Idiopathic pulmonary fibrosis (IPF) is a chronic disease in which healthy lung tissue is gradually replaced by scar tissue.

Interstitial lung disease (ILD) is a collective term for afflictions of the tissues around the air sacs in the lungs, and often presents as a shortness of breath or dry cough. Prolonged inflammation ...

Dysregulated bidirectional epithelial–mesenchymal crosstalk: A core determinant of lung fibrosis progression Understanding the cause of the lung scarring can lead to the development of biomarkers and ...

New research identifies a specific monocyte gene signature that predicts mortality in IPF, offering potential targets precision medicine.

Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...

A large-scale genomic investigation has identified new genetic risk factors for idiopathic pulmonary fibrosis (IPF) and revealed substantial overlap with pathways that also predispose individuals to ...

Cell-cell interactions via proteins and ligand-receptor interactions contribute to PF pathogenesis. Single-cell RNA genome sequencing technique and bio-informatics oriented approaches combined with ...

Nerandomilast is an oral, preferential PDE4B inhibitor approved in China for the treatment of adult patients with IPF and PPF. It was also approved by the U.S. Food and Drug Administration (FDA) for ...